JLJulio Llanos-Torres

Julio Llanos-Torres

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Julio Llanos-Torres has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    2312. COVID-19 risk factors before and after the vaccines among hospital workers: Have they changed?

    by Fernando Rosso, David E Rebellon-Sanchez, Julio Llanos-Torres, Eric Tafurt

    COVID-19 has been a major public health concern globally, and risk factors have played a crucial role in determining the outcomes of the disease. With the introduction of vaccines, the impact of these risk factors could change and alter the course of the pandemic. Ambispective observational study performed among hospital workers of a university hospital in Cali, Colombia. From March 6th, 2020, to February 28th, 2022. Risk factors were assessed with a self-reported survey. Using the aRR calculated for each of the five waves of COVID-19 in Colombia, mixed-effects models were constructed to obtain the association strengths in the pre- and post-vaccination era. A total of 480 patients, 71.8% were females. The median age was 32 years (27 - 39). In the pre vaccination era there were 169 (35.21%) COVID-19 cases and 165 cases (34.3%) in the post vaccination. In the pre-vaccination era, associated factors were being a healthcare worker (HCW) (aRR 2.12 (95%CI: 1.19-3.79)), technician (aRR 1.73 (1.26-2.38)), living with COVID-19 patients (aRR 2.10 (1.39-3.18)), immunosuppressive medication(aRR 3.88 (1.90-7.70)), self-perceived continuous exposure to COVID-19 patients (aRR 0.28 (0.21-0.37)), and a first COVID-19 episode during the first wave (aRR 0.05 (0.01-0.35)). In the post-vaccination era, COVID-19 history (aRR 0.49 (0.34-0.70)), vaccination in the past 6 months (aRR 0.13 (0.07-0.24)), positive anti-S antibodies in the last 3 months (aRR 0.55 (0.31-0.97)), and positive anti-N antibodies in the last 6 months (aRR 0.35 (0.17-0.74)) were associated. Risks factors for COVID-19 in pre and post vaccination era. In the pre-vaccination era, being a healthcare worker (HCW), technician, living with COVID-19 patients, immunosuppressive medication, self-perceived continuous exposure to COVID-19 patients and a first COVID-19 episode during the first wave were risk factors. while in the post-vaccination era, COVID-19 history, vaccination in the past 6 months positive anti-S antibodies in the last 3 months, and positive anti-N antibodies in the last 6 months were associated with COVID-19. This study highlights the dynamic nature of risk factors after the introduction of vaccination. Educational level, being a healthcare worker, working in hospitalization areas, and living with COVID-19 patients were significant risk factors before vaccination. While increased positivity and S-antibody levels linked to vaccination were associated to lower risk of COVID-19 in the post-vaccination era. All Authors: No reported disclosures

  • Open Access

    2311. Predictive cut-off values for anti-N and anti-S antibodies for COVID-19 risk identification

    by David E Rebellón Sánchez, Julio Llanos-Torres, Eric Tafurt, Fernando Rosso

    The role of anti-N and anti-S antibody tests as a monitoring strategy for identifying patients at risk of developing COVID-19 is not clearly elucidated. Our study explored in a cohort of hospital workers whether the positivity of these antibodies linked to infection and/or vaccination was associated with a decrease in the risk of infections and sought to estimate a predictive cut-off point for the development of COVID-19 in the first 6 months of measurement. A prospective observational study was conducted among hospital workers at a university hospital in Cali, Colombia. Measurements of COVID-19 antibodies were taken before the onset of the third, fourth, and fifth waves of COVID-19 cases. Anti-N and Anti-S total antibodies were measured using Elecsys® Anti-SARS-CoV-2 Immunoassay (Roche). We include 480 participants, 71.8% females and median age of 32 years (IQR: 27-39); 60.62% were healthcare workers involved in the care of COVID-19 patients. It was found that having a history of COVID-19 (aRR 0.49 (95% CI 0.34-0.70)), being vaccinated in the last 6 months (aRR 0.13 (95% CI 0.07-0.24)), having positive anti-N antibodies in the last 3 months (aRR 0.62 (95% CI 0.44-0.87)), and having positive anti-S antibodies in the last 3 months (aRR 0.55 (95% CI 0.31-0.97)) were associated with a lower risk of developing COVID-19. A cutoff point ≤ 150 COI for anti-N levels and ≤1,900 BAU/mL for anti-S levels was found to have a better predictive performance. The chosen cutoff point for anti-N achieved a sensitivity of 98.2%, with a specificity of 12.4%, a negative predictive value (NPV) of 98.5%, and a positive predictive value (PPV) of 10.2%, with an AUC of 0.55 for predicting COVID-19 in the next 6 months. Having anti-S antibodies ≤ 1900 BAU/mL was found to have a sensitivity of 58.1%, specificity of 55.5%, NPV of 85.3%, PPV of 22.9%, and an AUC of 0.63. Our study suggests that having a positive anti-N or anti-S antibodies result may be associated with a lower risk of developing COVID-19. We also identified predictive cut-off points for anti-N and anti-S antibody levels that may be useful in identifying individuals at a higher risk of developing COVID-19 in the next 6 months. However, further studies are needed to confirm these findings and determine their generalizability to other populations. All Authors: No reported disclosures

  • Open Access

    1505. Clinical characterization of TB/HIV naive coinfection patients enrolled in a TB program in Cali - Colombia.

    by Jenny Patricia Muñoz-Lombo, Julio Llanos-Torres, David E Rebellon-Sanchez, Sofía Alexandra Montes-Tello, José Fernando García-Goez, Fernando Rosso

    Although antiretroviral therapy (ART) is beneficial for patients with TB/HIV coinfection, there are issues associated with concomitant therapy administration such as overlapping drug toxicity profiles, drug interactions, and the possibility of developing immune reconstitution inflammatory syndrome (IRIS). The clinical experience in managing patients with TB who develop de novo HIV is poorly described in Colombia and the prevalence of IRIS in our context is unknown. This study aims to describe the clinical characteristics of patients with TB who develop de novo HIV coinfection and determine the prevalence of IRIS following treatment initiation. Retrospective, observational study. Patients in the TB program whit de novo HIV coinfection were included. A total of 39 patients were included. Most of the patients were male (64%) and of mixed race (58%) with an urban origin (92%). Smoking was documented in 24% of the patients and the Bacille Calmette-Guérin (BCG) TB vaccine was recorded in 48% of the patients. Pulmonary TB occurred in 74% of the patients, while miliary TB and lymph node involvement occurred in 26%. Meningeal TB and CNS TB were present in 15% of the patients, peritoneal TB in 18%, and pleural TB in 5.1%. More than 70% of the patients experienced weight loss and dyspnea (74% and 76%, respectively). Antiretroviral treatment was administered to 46% of the patients with EFV-AZT/3TC, to 21% with LPV/R+ABC/3TC, and to 14% with EFV+TDF/FTC. Individualized tuberculosis treatment was administered to 38.48% of the patients. Of the patients, 19% (5/27) developed IRIS, of which three developed TB-IRIS. The mortality rate was 2.6%, while the cure rate was 18%. our study sheds light on the clinical characteristics of patients with TB who develop de novo HIV coinfection in Colombia. The high prevalence of smoking and low prevalence of BCG vaccination among these patients are notable findings. Additionally, our study highlights the importance of individualized treatment for TB and the need for careful management of patients receiving ART to minimize the risk of developing IRIS. Further research is warranted to explore the prevalence of IRIS in our context and to develop strategies to reduce its incidence. All Authors: No reported disclosures


  • Open Access

    440. Steroid Use and Elevated Rates of Coinfections and Mortality in Mild-COVID-19 Patients

    by David E Rebellon-Sanchez, Julio Llanos-Torres, Carolina Álvarez-Ortega, Tania M Guzman-Gonzales, Sarita Rodríguez, Fernando Rosso

    Systemic corticosteroids are used to treat patients with COVID-19. Since the findings of the RECOVERY trial, steroids have been broadly used in critical patients. However, their use in patients with mild disease was unclear and may even be harmful. In the hard times of the pandemic in the absence of widely available vaccines or antivirals agents, hospital overcrowding, patients had to be referred to home care and steroids could be overused. The aim of this study was to explore the relationship between the use of corticosteroids, secondary infections and overall mortality in adults with COVID-19 A prospective observational study was performed in a university hospital in Cali, Colombia. Severity was assessed with NEWS score 2. The study included patients at various levels of severity, including patients admitted to the emergency department, inpatients, and those admitted to the intensive care unit A total of 12,227 patients were treated at our hospital during the first four waves of the pandemic. 54.8% were female, with median age of 45 years (IQR: 31 - 62). 68.5% were classified as mild COVID-19, 8.8% as moderate, and 22.68% as severe. 5.49% of patients were pregnant. Of all patients, 24.30% received corticosteroids upon admission, 11.6% developed secondary infections, and 8.4% died. Mild COVID-19 cases were 1,988 (wave 1), 2,147 (wave 2), 1,628 (wave 3), and 1,608 (wave 4). The proportions of corticosteroid used by waves were 4.3%, 7.18%, 12.5%, and 8.1%, respectively. Corresponding proportions for secondary infections were 2.80%, 5.26%, 6.14%, and 3.8%, while death proportions were 1.7%, 2.5%, 3.2%, and 2.1%. A positive correlation was found between corticosteroid use and secondary infection and mortality rates (Fig. 1). Correlation coefficients were r= 0.9 (p= 0.09) for corticosteroid use and mortality, r= 0.84 (p= 0.15) for corticosteroid use and secondary infection, and r= 0.94 (p= 0.01) for secondary infection and mortality. These correlations were not observed in moderate and severe COVID-19 cases A. Relationship in mild COVID-19 patients. B. Relationship in moderate-to-severe COVID-19 patients Our study shows that the use of corticosteroids in mild cases could correlate with a greater proportion of secondary infections and mortality All Authors: No reported disclosures

  • Open Access

    Co-Infection between Dengue Virus and SARS-CoV-2 in Cali, Colombia

    by Olga Lucia Agudelo-Rojas, David Esteban Rebellón-Sánchez, Julio Llanos Torres, Isabel Lucia Zapata-Vásquez, Sarita Rodríguez, Sebastián Robles-Castillo, Alejandro Tejada Vega, Luis Gabriel Parra-Lara, Fernando Rosso

    : The co-occurrence of COVID-19 with endemic diseases is a public health concern that may affect patient prognosis and outcomes. The objective of this study was to describe the clinical characteristics of patients with dengue virus (DENV) and SARS-CoV-2 co-infections and compare their outcomes against those of COVID-19 patients without dengue. A cross-sectional study was conducted in patients with SARS-CoV-2 infection who attended a single center in Cali, Colombia, from March 2020 to March 2021. All patients who were tested by both real-time polymerase chain reaction for SARS-CoV-2 and IgM/NS1 for DENV were included. Dengue was diagnosed as having either an IgM- or an NS1- positive test. A total of 90 patients were included (72 with COVID-19 only and 18 with co-infection). Patients with co-infection had more dyspnea (61.1% versus 22.2%; P = 0.003) as well as higher oxygen desaturation (53.3% versus 13.4%; P = 0.002) and neutrophil-to-lymphocyte ratio (5.59 versus 3.84; P = 0.038) than patients with COVID-19 alone. The proportion of patients classified with moderate to severe COVID-19 was higher in the co-infection group (88.3% versus 47.8%; P = 0.002). Also, co-infection was associated with an increased need for mechanical ventilation (P = 0.06), intensive care unit (ICU) initial management (P = 0.02), and ICU admission during hospitalization (P = 0.04) compared with COVID-19 only. The ICU mortality rate was 66.6% in patients with co-infection versus 29.4% in patients infected with only SARS-CoV-2 (P < 0.05). The possibility of DENV and SARS-CoV2 co-infection occurred in the convergence of both epidemic waves. Co-infection was associated with worse clinical outcomes and higher mortality in ICU-admitted patients than in patients with the COVID-19 only.